346617-98-9

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-(4-iodophenoxy)-, 1,1-dimethylethyl ester
• CAS NO: 346617-98-9
• Molecular Formula: C16H22INO3
• Molecular Weight: 403.26
• Mol File: 346617-98-9.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-(4-iodophenoxy)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-(4-iodophenoxy)-, 1,1-dimethylethyl ester(346617-98-9)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-(4-iodophenoxy)-, 1,1-dimethylethyl ester(346617-98-9)

Safety Data

• Hazardous Substances Data: 346617-98-9(Hazardous Substances Data)

Upstream product

• 352-34-1 4-fluoro-1-iodobenzene 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 540-38-5 p-Iodophenol 

Downstream Products

• 346617-99-0 4-[4-(4-methoxy-phenylsulfanyl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester 
• 955360-28-8 4-[(4-iodophenyl)oxy]piperidine trifluoroacetate 
• 684249-45-4 4-(4-iodophenoxy)piperidine 
• 1012330-94-7 tert-butyl 4-(4-(3-hydroxyprop-1-ynyl)phenoxy)piperidine-1-carboxylate 
• 1033055-22-9 tert-butyl 4-{-4-[4-(ethoxycarbonyl)-1H-pyrazol-1-yl]phenoxy}piperidine-1-carboxylate 
• 1033055-20-7 tert-butyl 4-{-4-[4-(pyrrolidin-1-ylcarbonyl)-1H-pyrazol-1-yl]phenoxy}piperidine-1-carboxylate 
• 955360-30-2 4-{4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl}-3-butyn-1-ol 
• 955360-31-3 4-{4-[(1-cyclobutyl-4-piperidinyl)oxy]phenyl}-1-butanol 
• 955360-29-9 1-cyclobutyl-4-(4-iodophenoxy)piperidine 
• 1220019-83-9 4-(4-iodophenoxy)piperidine hydrochloride 
• 1373010-41-3 1-isopropyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine 
• 684249-46-5 4-[(4-iodophenyl)oxy]-1-(1-methylethyl)piperidine 
• 921616-50-4 phenylmethyl 4-{4-[(1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinyl)oxy]phenyl}-3-oxo-1-piperazinecarboxylate 
• 889865-34-3 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

PLK-4 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following Structural Formula (I) and (II) and pharmaceutically acceptable salts thereof: (Formula (I)); (Formula (IV)). Compounds represented by this structural formula are kinase inhibitors and are, therefore, disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

Optimization of α-ketooxazole inhibitors of fatty acid amide hydrolase

A series of α-ketooxazoles containing conformational constraints in the flexible C2 acyl side chain of 2 (OL-135) and representative oxazole C5 substituents were prepared and examined as inhibitors of fatty acid amide hydrolase (FAAH). Exceptionally potent and selective FAAH inhibitors emerged from the series (e.g., 6, Ki = 200 and 260 pM for rat and rhFAAH). With simple and small C5 oxazole substituents, each series bearing a biphenylethyl, phenoxyphenethyl, or (phenoxymethyl)phenethyl C2 side chain was found to follow a well-defined linear relationship between -log Ki and Hammett σp of a magnitude (ρ = 2.7-3.0) that indicates that the substituent electronic effect dominates, confirming its fundamental importance to the series and further establishing its predictive value. Just as significantly, the nature of the C5 oxazole substituent substantially impacts the selectivity of the inhibitors whereas the effect of the C2 acyl chain was more subtle but still significant even in the small series examined. Combination of these independent features, which display generalized trends across a range of inhibitor series, simultaneously improves FAAH potency and selectivity and can provide exquisitely selective and potent FAAH inhibitors.